首页> 外文期刊>Journal of Medicinal Chemistry >Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists.
【24h】

Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists.

机译:利莫那班吡唑部分的生物立体置换:噻唑,三唑和咪唑作为有效和选择性的CB1大麻素受体拮抗剂的合成,生物学性质和分子模型研究。

获取原文
获取原文并翻译 | 示例
       

摘要

Series of thiazoles, triazoles, and imidazoles were designed as bioisosteres, based on the 1,5-diarylpyrazole motif that is present in the potent CB(1) receptor antagonist rimonabant (SR141716A, 1). A number of target compounds was synthesized and evaluated in cannabinoid (hCB(1) and hCB(2)) receptor assays. The thiazoles, triazoles, and imidazoles elicited in vitro( )()CB(1) antagonistic activities and in general exhibited considerable CB(1) vs CB(2) receptor subtype selectivities, thereby demonstrating to be cannabinoid bioisosteres of the original diarylpyrazole class. Some key representatives in the imidazole series showed potent pharmacological in vivo activities after oral administration in both a CB agonist-induced hypotension model and a CB agonist-induced hypothermia model. Molecular modeling studies showed a close three-dimensional structural overlap between the key compound 62 and rimonabant. A structure-activity relationship (SAR) study revealed a close correlation between the biological results in the imidazole and pyrazole series.
机译:基于有效的CB(1)受体拮抗剂利莫那班(SR141716A,1)中存在的1,5-二芳基吡唑基序,将噻唑,三唑和咪唑系列设计为生物等排体。合成了许多目标化合物,并在大麻素(hCB(1)和hCB(2))受体分析中进行了评估。噻唑,三唑和咪唑具有体外()()CB(1)拮抗活性,通常表现出相当大的CB(1)与CB(2)受体亚型选择性,从而证明是最初的二芳基吡唑类的大麻素生物等排体。咪唑系列的一些主要代表在CB激动剂诱导的低血压模型和CB激动剂诱导的低体温模型中均显示出口服给药后体内的有效药理活性。分子模型研究表明,关键化合物62和利莫那班之间存在紧密的三维结构重叠。结构-活性关系(SAR)研究表明,咪唑和吡唑系列的生物学结果之间存在密切的相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号